Supplementary Tables 1 through 4 and Supplementary Figures 1 through 5 from &lt;i&gt;In Vitro&lt;/i&gt; and &lt;i&gt;In Vivo&lt;/i&gt; Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing